SCHEMBL20154573

SCHEMBL20154573

COc1ccc(CN2CC3CCC(C2)N3C)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV6 Q9H1D0 1/20 0.56
PDE9A O76083 3/20 0.47
PDE1C Q14123 1/20 0.47
RET P07949 3/20 0.44
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
JAK3 P52333 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
SIGMAR1 Q99720 3/20 0.42
PRKAB2 O43741 1/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAG3 Q9UGI9 1/20 0.40
PRKAG2 Q9UGJ0 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40
CYP11B1 P15538 1/20 0.40
TLR9 Q9NR96 1/20 0.40
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070739 0.92 TRPV6 (0.50) TRPV6PDE9APDE1CRETJAK2
SCHEMBL20070533 0.88 TRPV6 (0.53) TRPV6PDE9APDE1CRETJAK2
SCHEMBL20148632 0.85 TRPV6 (0.56) TRPV6PDE9APDE1CRETJAK2
SCHEMBL20070749 0.83 TRPV6 (0.47) TRPV6PDE9APDE1CRETJAK2
SCHEMBL18291458 0.81 PDE9A (0.42) TRPV6PDE9APDE1CTLR9TLR8
SCHEMBL20160367 0.81 TRPV6 (0.48) TRPV6PDE9APDE1CRETJAK2
SCHEMBL20070737 0.81 TRPV6 (0.50) TRPV6RETSIGMAR1CYP11B1
SCHEMBL20070002 0.81 TRPV6 (0.50) TRPV6PDE9APDE1CRETJAK2
SCHEMBL20148630 0.80 TRPV6 (0.47) TRPV6PDE9APDE1CRETJAK2
SCHEMBL18290958 0.80 CPB1 (0.38) TRPV6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF TRPV6 4180/4885PDE9A 791/4885PDE1C 926/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF TRPV6 4180/4885PDE9A 791/4885PDE1C 926/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF TRPV6 4180/4885PDE9A 791/4885PDE1C 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.